Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

UBS
Federal Trade Commission
Harvard Business School
Queensland Health
Colorcon
Farmers Insurance
Medtronic
McKesson
McKinsey

Generated: May 20, 2018

DrugPatentWatch Database Preview

SODIUM HEPARIN Drug Profile

or, see our see our flat-rate plans

« Back to Dashboard

Which patents cover Sodium Heparin, and when can generic versions of Sodium Heparin launch?

Sodium Heparin is a drug marketed by Abraxis Pharm and Baxter Hlthcare and is included in two NDAs.

The generic ingredient in SODIUM HEPARIN is heparin sodium. There are seventy-seven drug master file entries for this compound. Fifteen suppliers are listed for this compound. Additional details are available on the heparin sodium profile page.
Summary for SODIUM HEPARIN
Drug patent expirations by year for SODIUM HEPARIN
Synonyms for SODIUM HEPARIN
(2S,3S,4R,5R,6R)-6-{[(2S,3S,4S,5R,6S)-6-{[(2R,3S,4S,5R)-2-carboxy-4,6-dihydroxy-5-(sulfooxy)oxan-3-yl]oxy}-2-hydroxy-4-(sulfomethyl)-5-(sulfooxy)oxan-3-yl]oxy}-3-{[(2R,3R,4R,5S,6R)-3-acetamido-4,5-dihydroxy-6-[(sulfooxy)methy
CA000776
CHEMBL526514
D05GGN
D0UX6Z
GTPL4214
HEPARIN REACTION PRODUCTS WITH N N-DIDODECYL-N-METHYL-1-DODECANAMINIUM CHLORIDE
Heparin (buccal)
Heparin Sodium 10,000 Units And Dextrose 5% In Plastic Container
Heparin sodium 10,000 units in dextrose 5% in plastic container
Heparin sodium 25,000 units in dextrose 5%
Heparin sodium 25,000 units in sodium chloride 0.9%
Heparin sodium 5,000 units in sodium chloride 0.45%
Heparin sulphate
Heparinsodiumsalt
HepFlush
ZFGMDIBRIDKWMY-PASTXAENSA-N

US Patents and Regulatory Information for SODIUM HEPARIN

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Abraxis Pharm SODIUM HEPARIN heparin sodium INJECTABLE;INJECTION 017033-002 Approved Prior to Jan 1, 1982 DISCN No No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Baxter Hlthcare SODIUM HEPARIN heparin sodium INJECTABLE;INJECTION 017036-001 Mar 4, 1988 DISCN No No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Abraxis Pharm SODIUM HEPARIN heparin sodium INJECTABLE;INJECTION 017033-003 Approved Prior to Jan 1, 1982 DISCN No No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Abraxis Pharm SODIUM HEPARIN heparin sodium INJECTABLE;INJECTION 017033-004 Approved Prior to Jan 1, 1982 DISCN No No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

or, see our see our flat-rate plans

or, see our see our flat-rate plans

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Federal Trade Commission
Chinese Patent Office
Covington
Citi
Argus Health
Dow
Harvard Business School
UBS
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.